Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
17
02
2023
revised:
29
12
2023
accepted:
05
04
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
4
6
2024
Statut:
ppublish
Résumé
Cancer cells exhibit metabolic plasticity to meet oncogene-driven dependencies while coping with nutrient availability. A better understanding of how systemic metabolism impacts the accumulation of metabolites that reprogram the tumor microenvironment (TME) and drive cancer could facilitate development of precision nutrition approaches. Using the Hi-MYC prostate cancer mouse model, we demonstrated that an obesogenic high-fat diet (HFD) rich in saturated fats accelerates the development of c-MYC-driven invasive prostate cancer through metabolic rewiring. Although c-MYC modulated key metabolic pathways, interaction with an obesogenic HFD was necessary to induce glycolysis and lactate accumulation in tumors. These metabolic changes were associated with augmented infiltration of CD206+ and PD-L1+ tumor-associated macrophages (TAM) and FOXP3+ regulatory T cells, as well as with the activation of transcriptional programs linked to disease progression and therapy resistance. Lactate itself also stimulated neoangiogenesis and prostate cancer cell migration, which were significantly reduced following treatment with the lactate dehydrogenase inhibitor FX11. In patients with prostate cancer, high saturated fat intake and increased body mass index were associated with tumor glycolytic features that promote the infiltration of M2-like TAMs. Finally, upregulation of lactate dehydrogenase, indicative of a lactagenic phenotype, was associated with a shorter time to biochemical recurrence in independent clinical cohorts. This work identifies cooperation between genetic drivers and systemic metabolism to hijack the TME and promote prostate cancer progression through oncometabolite accumulation. This sets the stage for the assessment of lactate as a prognostic biomarker and supports strategies of dietary intervention and direct lactagenesis blockade in treating advanced prostate cancer. Lactate accumulation driven by high-fat diet and MYC reprograms the tumor microenvironment and promotes prostate cancer progression, supporting the potential of lactate as a biomarker and therapeutic target in prostate cancer. See related commentary by Frigo, p. 1742.
Identifiants
pubmed: 38831751
pii: 745520
doi: 10.1158/0008-5472.CAN-23-0519
doi:
Substances chimiques
Lactic Acid
33X04XA5AT
Proto-Oncogene Proteins c-myc
0
MYC protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1834-1855Subventions
Organisme : AIRC Foundation for Cancer Research
ID : IG-21966
Organisme : Canadian Institutes of Health Research (CIHR)
ID : PJT-180368
Organisme : Canadian Institutes of Health Research (CIHR)
ID : PJT-162246
Organisme : Dana-Farber Cancer Institute (DFCI)
ID : Claudia Adams Barr Award in Innovative Basic Cancer Research
Organisme : U.S. Department of Defense (DOD)
ID : PC150263
Organisme : World Cancer Research Fund International (WCRF)
ID : IIG_FULL_2022_020
Informations de copyright
©2024 The Authors; Published by the American Association for Cancer Research.